Galectin-3 As a Risk Factor for Adverse Cardiovascular Events in Long-Term Monitoring of Patients with Myocardial Infarction of the Right Ventricle on the Background of the Q-Myocardial Infarction of the Left Ventricle Posterior Wall

V.Y. Tseluyko, T.A. Lozova, O.S. Sasyuk

Abstract


It has studied the prognostic value of galectin-3 in the development of cardiovascular complications at 30-month follow-up of 155 patients with myocardial infarction of the right ventricle on the background of the ­Q-myocardial infarction of the left ventricle posterior wall. The level of galectin-3 was determined on the 2nd day of acute myocardial infarction and in 6 months of follow-up (Platinun ELISA). It has proved the prognostic significance of galectin-3 in the development of unstable angina, myocardial re-infarction, stroke and cardiovascular death within 30 months. The connection has been established between the high concentration of galectin-3 in 6 months after the right ventricle myocardial infarction incidence and the rate of the combined cardiovascular endpoint.


Keywords


galectin-3; myocardial infarction of the right ventricle; cardiovascular complications; predictors

References


Voronkov L.H., Amosova K.M., Bahriy A.E. ta in. Rekomendatsiyi z diahnostyky ta likuvannya khronichnoyi sertsevoyi nedostatnosti (2012) // Sertseva nedostatnist'. - 2012. - #3. - S. 60-96.

De Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ. Galectin-3: a novel mediator of heart failure development and progression. European Journal of Heart Failure 2009;11:811-817. doi:10.1093/eurjhf/hfp097.

Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-Martinez E, de Boer RA, Poirier F, Lacolley P, Zannad F, Rossignol P, López-Andrés N. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol. 2013;33(1):67-75. doi: 10.1161/ATVBAHA.112.300569.

DeFilippi C., Felker M. Galectin-3 in Heart Failure – Linking Fibrosis, Remodeling and Progression. US Cardiology2010;7(1):67-70.

Doehner W. Diagnostic biomarkers in cardiovascular disease. Diagnostic biomarkers in cardiovascular disease: the proteomics approach. Eur. Heart J. 2012; 33:2317-2324. Doi:org/10.1093/eurheartj/ehs244.

Falcone C, Lucibello S, Mazzucchelli I, Bozzini S, D'Angelo A, Schirinzi S, Totaro R, Falcone R, Bondesan M, Pelissero G. Galectin-3 plasma levels and coronary artery disease: a new possible biomarker of acute coronary syndrome. Int J Immunopathol Pharmacol. 2011;24(4):905-13.

Halkin A, Singh M, Nikolsky E, Grines CL, Tcheng JE, Garcia E, Cox DA, Turco M, Stuckey TD, Na Y, Lansky AJ, Gersh BJ, O’Neilli WW, Mehran R, Stone GW. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction. The Cardillak Risk Score. J Am CollCardiol. 2005;45 (9):1397 - 1405. doi:10.1016/j.jacc.2005.01.041

Hamon M, Agostini D, Page O, RiddellJW, Hamon M.l. Prognostic impact of right ventricular involvement in patients with acute myocardial infarction: Meta-analysis. Crit Care Med. 2008;36 (7):2023–2033. doi: 10.1097/CCM.0b013e31817d213d.

Grandin EW, Jarolim P, Murphy SA, Ritterova L, Cannon CP, Braunwald E, Morrow DA. Galectin-3 and the development of heart failure after acute coronary syndrome: a pilot experience from PROVE IT-TIMI 22. Clinical Chemistry 2012;58:267-273. Doi: 10.1373/clinchem.2011.174359.

Jensen CJ, Jochims M, Hunold P, Sabin GV, Schlosser T, Bruder O. Right ventricular involvement in acute left ventricular myocardial infarction: prognostic implications of MRT findings. AJR Am J Roentgenol. 2010 Mar;194(3):592-8. doi: 10.2214/AJR.09.2829.

Kramer F. Galectin-3: clinical utility and prognostic value in patients with heart failure. Reasearch Reports in Clinical Cardiology 2013;4:13-22. Doi: 10.2147/RRCC.S28562

Lok DJA, Van Der Meer P, de la Porte PW B-A, Lipsis E, Van Wijngaarden J. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 2010;99:323–328. Doi:10.1007/s00392-010-0125-y.

Ninkovic VM, Perunicic JZ, Ninkovic SM, Miloradowic VM, Vojislav G, Jakovljevic DG. Predictors of In-Hospital Mortality in Patients with Acute Inferior Infarction of the Left Ventricle Accompanied by Right Ventricular Infarction when Treated with Percutaneous Coronary Intervention . J Clin Exp Cardiolog 2013;4: 253-258. Doi:10.4172/2155-9880.1000253

Pereira A., Franken R., Sproviery SR, Golin V. Impact on hospital mortality and morbidity of right ventricular involvement among patients with acute left ventricular infarction // Sao Paulo Med J. 2006;124(4):186-191.

Shan RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL. Galectin-3, cardiac structure and function, and long-term mortality in patients with acute decompensated heart failure // Eur J Heart Fail. 2010 August; 12(8): 826–832. doi: 10.1093/eurjhf/hfq091

Stanley G, Mansi P, Ashok T. Clinical profile and in-hospital outcome of patients with right ventricular myocardial infarction. International Journal of Clinical Medicine 2014;5:459-463. Doi: 10.4236/ijcm.2014.58064.

Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K,Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van 't Hof A, Widimsky P, Zahger D. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J. 2012 Oct;33(20):2569-619. doi: 10.1093/eurheartj/ehs215.




DOI: https://doi.org/10.22141/2224-0586.5.76.2016.76438

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 EMERGENCY MEDICINE

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru